Participant flow36

How many started, completed or left each group, period by period.

21 to 36 of 36

Period	Milestone	Group	Participants
Overall Study	Completed Study	Aprocitentan 10 mg	79
Overall Study	Completed Study	Aprocitentan 25 mg	76
Overall Study	Completed Study	Aprocitentan 50 mg	78
Overall Study	Completed Study	Lisinopril 20 mg	75
Overall Study	COMPLETED	Placebo	70
Overall Study	COMPLETED	Aprocitentan 5 mg	74
Overall Study	COMPLETED	Aprocitentan 10 mg	75
Overall Study	COMPLETED	Aprocitentan 25 mg	70
Overall Study	COMPLETED	Aprocitentan 50 mg	70
Overall Study	COMPLETED	Lisinopril 20 mg	71
Overall Study	NOT COMPLETED	Placebo	12
Overall Study	NOT COMPLETED	Aprocitentan 5 mg	8
Overall Study	NOT COMPLETED	Aprocitentan 10 mg	7
Overall Study	NOT COMPLETED	Aprocitentan 25 mg	12
Overall Study	NOT COMPLETED	Aprocitentan 50 mg	11
Overall Study	NOT COMPLETED	Lisinopril 20 mg	10

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02603809/flow?page=2